Dalpiciclib with endocrine therapy treats HR-positive advanced breast cancer in visceral crisis

In advanced breast cancer, few clinical situations are as ominous as visceral crisis — the rapid, life-threatening spread of disease to organs such as the liver or lungs, accompanied by symptomatic deterioration. Patients with hormone receptor–positive, HER2-negative disease who develop visceral crisis are typically pushed toward chemotherapy, because standard endocrine therapy is considered too slow to control organ-threatening disease. But a new phase 2 clinical trial reported in Nature Cancer suggests that a targeted oral drug may give many of these women a survival outcome that once seemed out of reach.

The DARVIN trial, a multicenter, nonrandomized phase 2 study led by investigators including H. Mo, Y. Teng and L. Cai, evaluated dalpiciclib — a selective CDK4/6 inhibitor — in combination with endocrine therapy in women with HR-positive/HER2-negative advanced breast cancer experiencing visceral crisis. The results were striking: of 53 participants enrolled, 49 survived beyond six months, translating into a six-month survival rate of 92.5 percent, with a 95 percent confidence interval ranging from 81.8 to 97.9 percent. The study met its primary endpoint, and the finding represents one of the strongest signals yet that CDK4/6 blockade can meaningfully change outcomes in this notoriously fragile patient population.

To understand why this matters, it helps to appreciate the biology. HR-positive breast cancers remain dependent on the estrogen receptor signaling axis, which drives cell-cycle progression. CDK4/6 inhibitors such as dalpiciclib work downstream of the estrogen receptor, blocking the cyclin D–CDK4/6 complex that phosphorylates the retinoblastoma protein and thereby releases the cell into the DNA synthesis phase of the cell cycle. By halting this phosphorylation step, the drug enforces a G1 arrest, effectively putting tumor cells into a state of senescence-like quiescence. Combined with endocrine therapy — which suppresses estrogen signaling at the receptor level — the two agents attack the same proliferative machinery at complementary points. In ordinary HR-positive metastatic disease, this combination is already standard of care. The visceral crisis setting is different: the disease is behaving aggressively, organs are failing under tumor burden, and clinicians have historically doubted whether a slow-acting hormonal approach could keep pace.

The trial’s design reflected that skepticism. Rather than measuring tumor shrinkage alone, the investigators chose six-month survival as the primary endpoint — a hard, clinically meaningful measure of whether patients could actually live long enough to benefit from treatment. Secondary endpoints included overall survival, progression-free survival, time to treatment failure, the three-month treatment failure rate, duration of disease control, objective response rate, disease control rate and safety. This endpoint architecture is deliberately patient-centered: in visceral crisis, where median survival in historical cohorts can be measured in a few months, simply keeping the majority of patients alive at half a year is a consequential goal.

The secondary outcomes painted a consistent picture of durable benefit. The objective response rate — the proportion of patients whose tumors shrank measurably — was 26.4 percent, while the disease control rate, which includes both shrinkage and stable disease, reached 79.2 percent. Only 22.6 percent of patients experienced treatment failure within the first three months, indicating that the vast majority of patients obtained at least short-term control of their disease during the most dangerous window. The median progression-free survival was 11.2 months (95 percent CI: 7.6–19.3), a duration that exceeds what many observers would have predicted for a population this ill. Duration of disease control reached 14.1 months (95 percent CI: 8.4–21.5), and time to treatment failure was 10.2 months (95 percent CI: 6.4–15.6). Notably, the median overall survival had not been reached at the time of analysis — meaning that more than half of the enrolled patients were still alive when the data were cut, a remarkable fact for a cohort defined by visceral crisis.

Safety data were consistent with the known profile of CDK4/6 inhibitors. The most common grade 3 or higher adverse events were hematologic: decreased neutrophil counts occurred in 77.4 percent of patients and decreased white blood cell counts in 54.7 percent. These effects reflect the drug’s mechanism of action on normal bone marrow cells, which also use the CDK4/6 pathway for proliferation. Importantly, neutropenia caused by CDK4/6 inhibition is typically reversible and rarely complicated by infection in the way chemotherapy-induced neutropenia can be, because the drug preserves lymphocyte populations relatively well. The data suggest that, with appropriate monitoring and dose modification, the regimen was manageable even in a high-acuity population.

Perhaps the most intriguing finding of the study, however, lies beyond the survival curves. In exploratory analyses, the investigators examined cell-free DNA — fragments of tumor and host DNA circulating in the blood — and stratified patients by the contribution of monocyte-derived cfDNA at baseline. Patients whose baseline monocyte-derived cfDNA level was below a threshold of 0.0581 had significantly worse overall survival, with a hazard ratio of 4.79 (95 percent CI: 1.05–45.47, P = 0.0394). The authors interpret this as evidence of a “molecular crisis” — a systemic inflammatory and immune state detectable in the bloodstream that predicts poor outcomes even among patients receiving an effective regimen. The concept is compelling: it suggests that visceral crisis is not merely a matter of tumor burden in organs, but of a broader biological state in which host immune and inflammatory dynamics, measurable through liquid biopsy, define prognosis.

The implications of this biomarker finding are twofold. Clinically, if validated, monocyte-derived cfDNA could help identify which patients with apparent visceral crisis might need escalation beyond endocrine-based therapy — for example, to chemotherapy — and which could safely remain on a CDK4/6 inhibitor combination. Scientifically, it reframes visceral crisis as a measurable molecular phenotype rather than a purely radiographic or symptomatic category. Circulating DNA carrying monocyte-associated signatures may reflect an immune system in distress, or a tumor microenvironment that has shifted toward a pro-inflammatory, treatment-resistant state. Disentangling that biology could open new therapeutic avenues beyond cell-cycle inhibition.

The DARVIN results arrive amid growing attention to how CDK4/6 inhibitors are deployed in the sequencing of metastatic breast cancer treatment. Dalpiciclib, developed in China and approved there for HR-positive/HER2-negative advanced breast cancer, joins abemaciclib, palbociclib and ribociclib in a class that has transformed outcomes across the disease continuum. Most prior evidence in visceral crisis has come from subgroup analyses of larger trials or from retrospective series, and those data have been inconsistent. A dedicated prospective trial — even a single-arm, nonrandomized one — specifically designed around visceral crisis patients is unusual, and the 92.5 percent six-month survival figure provides a benchmark against which future studies and combination strategies can be measured.

Caveats remain. The trial was nonrandomized and enrolled 53 patients, so the results cannot exclude selection effects, and there is no internal control arm against which to compare the survival benefit. Median overall survival was not reached, meaning longer follow-up will be needed to characterize the ultimate duration of benefit. The cfDNA threshold finding is exploratory and described with wide confidence intervals, and it will require independent validation before influencing practice. Nevertheless, the study is registered (ClinicalTrials.gov: NCT05431504) and the investigators argue that the data support further evaluation of dalpiciclib plus endocrine therapy in this population, ideally in randomized settings that could also test biomarker-guided strategies.

For patients and clinicians facing visceral crisis today, the study adds weight to a shifting consensus: that aggressive HR-positive disease in organs is not automatically synonymous with chemotherapy, and that rapidly acting endocrine-CDK4/6 combinations — under close monitoring — can achieve both tumor control and survival. As the field moves toward integrating liquid biopsy readouts such as monocyte-derived cfDNA into routine decision-making, the DARVIN trial stands as an early signal that molecular profiling may eventually distinguish which patients in crisis will thrive on targeted therapy and which truly need something more. The broader lesson is that “visceral crisis,” long treated as a monolithic red flag in breast cancer oncology, is being dismantled into biological substates — some of which, it turns out, are far more treatable than their reputation suggests.